Stockscreener 앱 받기
128.60
0.05%
0.06
전일 마감가:
$128.54
열려 있는:
$128.77
하루 거래량:
1.17M
Relative Volume:
0.52
시가총액:
$13.67B
수익:
$612.78M
순이익/손실:
$-86.37M
주가수익비율:
-147.82
EPS:
-0.87
순현금흐름:
$-62.91M
1주 성능:
+0.61%
1개월 성능:
+1.66%
6개월 성능:
+69.90%
1년 성능:
+75.49%
1일 변동 폭
$128.52
$128.77
1주일 범위
$127.91
$128.77
52주 변동 폭
$62.78
$128.77
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
명칭
Intra Cellular Therapies Inc
전화
(646) 440-9333
주소
135 ROUTE 202/206, BEDMINSTER, NY
ITCI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-31 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2024-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-11 | 개시 | TD Cowen | Outperform |
| 2023-04-20 | 개시 | Morgan Stanley | Overweight |
| 2022-08-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-22 | 개시 | Piper Sandler | Neutral |
| 2022-02-16 | 개시 | Goldman | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2020-12-15 | 개시 | BofA Securities | Buy |
| 2020-12-10 | 개시 | Goldman | Buy |
| 2020-02-20 | 개시 | Evercore ISI | Outperform |
| 2020-01-31 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-12-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-12 | 개시 | Jefferies | Buy |
| 2018-02-26 | 개시 | JP Morgan | Overweight |
| 2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-11-08 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-09-07 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-09-29 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-09-29 | 다운그레이드 | SunTrust | Buy → Neutral |
모두보기
Intra Cellular Therapies Inc 주식(ITCI)의 최신 뉴스
Intra-Cellular: Q4 Earnings Snapshot - CTPost
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates - MSN
Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
CAPLYTA’s Strong Market Adoption Propels Its Rise as a Leading Antipsychotic Therapy | DelveInsight - GlobeNewswire Inc.
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by TimesSquare Capital Management LLC - MarketBeat
Intra-Cellular Therapies, Inc. SEC 10-K Report - TradingView
Form 10-K Intra-Cellular Therapies For: Dec 31 - StreetInsider.com
Intra-Cellular: Q4 Earnings Snapshot -February 21, 2025 at 08:18 am EST - Marketscreener.com
Intra-Cellular Therapies Q4 Net Loss Narrows, Revenue Rises -February 21, 2025 at 08:17 am EST - Marketscreener.com
Earnings Flash (ITCI) Intra-Cellular Therapies Posts Q4 Net Loss $0.16 a Share, vs. FactSet Est of $0.07 Loss - Marketscreener.com
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Principal Financial Group Inc. Reduces Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Savant Capital LLC Cuts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 12-Month HighWhat's Next? - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Update - MarketBeat
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat - MSN
StockNews.com Begins Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Quantum Private Wealth LLC - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 1-Year HighHere's What Happened - MarketBeat
(ITCI) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Intra-Cellular Therapies Stock Soars to All-Time High of $128.01 - MSN
Rep. Josh Gottheimer Sells Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock - MarketBeat
Legato Capital Management LLC Increases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
abrdn plc Has $19.13 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Holdings Lessened by Calamos Advisors LLC - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Significant Growth in Short Interest - MarketBeat
UBS Adjusts Price Target on Intra-Cellular Therapies to $132 From $87, Maintains Neutral Rating - Marketscreener.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by China Universal Asset Management Co. Ltd. - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Downgraded by Canaccord Genuity Group to Hold - MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
KBC Group NV Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Intra Cellular Therapies Inc (ITCI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Intra Cellular Therapies Inc 주식 (ITCI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Option Exercise |
12.73 |
51,000 |
649,230 |
1,121,329 |
| Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Sale |
85.80 |
51,000 |
4,375,659 |
1,070,329 |
| Mates Sharon | Chairman and CEO |
Dec 05 '24 |
Sale |
84.08 |
51,697 |
4,346,842 |
1,070,329 |
1.72%
1.53%
자본화:
|
볼륨(24시간):